Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 2 institutions in 1 country.
Brooke B BartowDepartment of Pathology, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Gene P SiegalDepartment of Pathology, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0003-3857-3368
Ceren YalnizDepartment of Radiology, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0003-3685-4799
Ahmed M ElkhananyDepartment of Breast Medical Oncology, Division of Hematology & Oncology, The University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0001-7681-6872
Lei HuoDepartment of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Qingqing DingDepartment of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Aysegul A SahinDepartment of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hua GuoDepartment of Pathology, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Cristina Magi-GalluzziDepartment of Pathology, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0003-1219-3797
Shuko HaradaDepartment of Pathology, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Xiao HuangDepartment of Pathology, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
University of Alabama at Birmingham · USThe University of Texas MD Anderson Cancer Center · US
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPis) have demonstrated antitumor activity in cancers with a homologous recombination deficiency (HRD) and have recently been approved by the FDA for the treatment of germline
Indexed as
advanced-stage breast carcinomaBRCAhomologous recombination genesloss of heterozygositymolecular profiling
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Mutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Advanced-Stage Breast Carcinoma. · full record | OpenQuestion